VR

Vandna Rani

Active Director Director DIN 11061998
DIN 11061998 First appointment Jun 2025 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 2 active board seats
Total affiliations 2 Since Jun 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Vandna Rani

Data last updated:

Vandna Rani is a Director at Virexa Drugs Private Limited (since 2025) and Director at Edwell Pharmaceuticals Private Limited (since 2025). The companies operate in Pharma.

DIN 11061998
Primary Designation Director
Industry Pharma
First Appointment 24 Jun 2025
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Virexa Drugs Private Limited U21001HR2025PTC132935
Director18 Jul 20252025Active
Director24 Jun 20252024Active

Directorship timeline

Open interactive timeline →
Edwell Pharmaceuticals Private Limited
Virexa Drugs Private Limited
Premium access

Shareholding and investment profile for Vandna Rani

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Vandna Rani

Vandna Rani currently holds 2 directorships: Virexa Drugs Private Limited (Director, since 18 Jul 2025); Edwell Pharmaceuticals Private Limited (Director, since 24 Jun 2025).

Vandna Rani was first appointed on 24 Jun 2025 as Director at Edwell Pharmaceuticals Private Limited.

The current boards of Vandna Rani's companies include Gurpreet Kaur (Virexa Drugs Private Limited), Vikas Singh (Virexa Drugs Private Limited), Hukam Chand Malik (Edwell Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available